Andrea Corbingi

Latina, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

A case of T-prolymphocytic leukemia harboring RAS mutation.

A case of T-prolymphocytic leukemia harboring RAS mutation.

Journal: Annals of hematology
Published: December 31, 2025

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Journal: Annals of hematology
Published: August 30, 2025

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Journal: American journal of hematology
Published: August 08, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances
Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances
Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances
Published: May 19, 2025

Asciminib and pulsed ATRA as post-remission therapy in T315I mutated PML-RARA-positive blast crisis of chronic myeloid leukemia.

Asciminib and pulsed ATRA as post-remission therapy in T315I mutated PML-RARA-positive blast crisis of chronic myeloid leukemia.

Journal: Annals of hematology
Published: May 11, 2025

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Journal: Blood advances
Published: March 18, 2025

The role of the immune system in progressive multifocal leukoencephalopathy: a comparative analysis of two cases following autologous and allogeneic hematopoietic stem cell transplantation.

The role of the immune system in progressive multifocal leukoencephalopathy: a comparative analysis of two cases following autologous and allogeneic hematopoietic stem cell transplantation.

Journal: Annals of hematology
Published: December 20, 2024

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Journal: Hematological oncology
Published: November 15, 2024

Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.

Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.

Journal: British journal of haematology
Published: July 11, 2024

Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.

Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.

Journal: Annals of hematology
Published: June 24, 2023
Showing 1-12 of 23

Last Updated: 09/26/2026